Eloxx Pharmaceuticals, Inc.
ELOX Nasdaq
SEC CIK 1035354
Follow Eloxx Pharmaceuticals
Weekly email: filings, results
Net income
−$5.5M
−1479.2% vs same quarter last year
EPS, diluted
−$0.49
+15.5% vs same quarter last year
Operating cash flow
−$4.3M
−149.5% vs same quarter last year
Operating income
−$6M
−1988.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$6M |
| FY24 | $6.4M | −$3.1M |
| FY23 | $0 | −$17.1M |
| FY22 | - | −$36.1M |
| FY21 | - | −$66.7M |
| FY20 | - | −$34.6M |
| FY19 | - | −$50.9M |
| FY18 | - | −$47.2M |
| FY17 | - | −$21.2M |
| FY16 | - | −$9.8M |
| FY15 | - | - |
| FY14 | $182.2K | −$9.2M |
| FY13 | $7.8K | −$6.1M |
| FY12 | $200K | −$5.1M |
| FY11 | - | −$7.3M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | −38.8% | −49.4% |
| FY23 | - | - |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
| FY15 | - | - |
| FY14 | −5019.9% | −5062.4% |
| FY13 | −59476.9% | −78303.4% |
| FY12 | −2705.8% | −2533.1% |
| FY11 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | −$31.9M |
| FY21 | −$35.1M |
| FY20 | - |
| FY19 | −$39.4M |
| FY18 | −$31.6M |
| FY17 | −$16.2M |
| FY16 | −$8.9M |
| FY15 | −$5.7M |
| FY14 | −$4.9M |
| FY13 | −$3.9M |
| FY12 | −$4.4M |
| FY11 | −$5.4M |
- Eloxx Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Eloxx Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | −49.4% | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −37.8% |
| FY14 | −5062.4% | −35.5% |
| FY13 | −78303.4% | −37.1% |
| FY12 | −2533.1% | −29.1% |
| FY11 | - | −27.9% |